- Home
- ELLO vs THRD Comparison
ELLO vs THRD Comparison
Compare ELLO & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- THRD
- Stock Information
- Founded
- ELLO 1987
- THRD 2019
- Country
- ELLO Israel
- THRD United States
- Employees
- ELLO N/A
- THRD N/A
- Industry
- ELLO Electric Utilities: Central
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- THRD Health Care
- Exchange
- ELLO Nasdaq
- THRD Nasdaq
- Market Cap
- ELLO 208.2M
- THRD 238.7M
- IPO Year
- ELLO 1995
- THRD 2022
- Fundamental
- Price
- ELLO N/A
- THRD $5.50
- Analyst Decision
- ELLO
- THRD Hold
- Analyst Count
- ELLO 0
- THRD 3
- Target Price
- ELLO N/A
- THRD $5.00
- AVG Volume (30 Days)
- ELLO 4.7K
- THRD 232.9K
- Earning Date
- ELLO 06-30-2025
- THRD 08-07-2025
- Dividend Yield
- ELLO N/A
- THRD N/A
- EPS Growth
- ELLO N/A
- THRD N/A
- EPS
- ELLO 0.43
- THRD N/A
- Revenue
- ELLO $44,405,534.00
- THRD N/A
- Revenue This Year
- ELLO N/A
- THRD N/A
- Revenue Next Year
- ELLO N/A
- THRD N/A
- P/E Ratio
- ELLO $45.19
- THRD N/A
- Revenue Growth
- ELLO N/A
- THRD N/A
- 52 Week Low
- ELLO $11.30
- THRD $3.18
- 52 Week High
- ELLO $20.81
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- ELLO 61.85
- THRD 65.61
- Support Level
- ELLO $16.61
- THRD $5.40
- Resistance Level
- ELLO $18.54
- THRD $5.47
- Average True Range (ATR)
- ELLO 0.89
- THRD 0.05
- MACD
- ELLO 0.31
- THRD -0.02
- Stochastic Oscillator
- ELLO 77.96
- THRD 40.00
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.